Sepsis and septic shock


State-of-the-art therapy for patients with endotoxic septic shock

Septic shock is associated with an unacceptable high mortality and a significant economic burden to the sanitary system. Endotoxin is the most potent trigger of the septic cascade and during the progress of sepsis, endotoxin levels can increase up to 1000 fold, even when cultures result negative for Gram-negative bacteria.

Toraymyxin®  Polymyxin B hemoperfusion therapy – from Toray Medical Ltd. (Japan), is the state-of-the-art therapy for endotoxin removal in septic shock patients. More than 200,000 patients have been treated with this innovative therapy and more than 400 peer-reviewed articles have been published, demonstrating the beneficial effects on hemodynamics, organ function and mortality. Toraymyxin® is now available in two versions: PMX-20R device for patients with adult body volume and PMX-05R device for patients with reduced body volume.

EAA™Endotoxin Activity Assay – is the only FDA approved diagnostic assay to detect endotoxin activity in human whole blood. The EAA™ diagnostic test is performed in less than 30 minutes. EAA™ is the diagnostic assay to identify patients with endotoxic septic shock.


Chronic kidney disease


A personalized therapy based on the individual needs of each patient


Acute kidney injury


HEMOFEELTM is a new membrane for continuous renal support made of polymethylmethacrylate, a highly hemo- and biocompatible material designed by TORAY – a global leader in advanced materials.

Focus on



ERA-EDTA 2021 is held virtually from 05-08 June 2021.
TORAY is supporting the symposium entitled “Renaissance of patient hemodialysis – novel PMMA membrane for diversified hemodialysis” on June 7th at 13.30-14.30.


e-SMART 2021

We are supporting various scientific and educational events at the e-SMART meeting, the virtual meeting in anesthesia and resuscitation in intensive care, taking place on May 24-28, 2021.



The webinar entitled “Endotoxemia and role of Polymyxin B hemoperfusion in the cardiovascular intensive care unit” held in collaboration with ITACTA (Italian Association of Cardiothoracic Anaesthesiologists)is now available ON-DEMAND. This webinar aims to describe and discuss the pathogenic action of endotoxemia in various clinical contests of patients hospitalized in a cardiovascular intensive care unit and the role of Polymyxin B hemoperfusion as possible therapeutic option in adult and pediatric patients.